Listed

Relmada Therapeutics, Inc.: Form 10-Q for the period ended Dec 31, 2017

Filed with the SEC on Feb 12, 2018 and accepted by EDGAR at Feb 12, 2018, 16:32 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-10-01 to 2017-12-31$150.7kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2017-07-01 to 2017-12-31$316.5kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-10-01 to 2017-12-31−$1.5mus-gaap:OperatingIncomeLoss
Operating income6 months2017-07-01 to 2017-12-31−$2.4mus-gaap:OperatingIncomeLoss
Net income3 months2017-10-01 to 2017-12-31−$1.4mus-gaap:NetIncomeLoss
Net income6 months2017-07-01 to 2017-12-31−$2.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-10-01 to 2017-12-31−$0.11us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2017-07-01 to 2017-12-31−$0.19us-gaap:EarningsPerShareDiluted
Basic EPS3 months2017-10-01 to 2017-12-31−$0.11us-gaap:EarningsPerShareBasic
Basic EPS6 months2017-07-01 to 2017-12-31−$0.19us-gaap:EarningsPerShareBasic
Operating cash flow6 months2017-07-01 to 2017-12-31−$2.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2017-07-01 to 2017-12-31$2.6kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2017-12-31$5.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-12-31$6.2mus-gaap:AssetsCurrent
Total assetsAt period end2017-12-31$6.6mus-gaap:Assets
Current liabilitiesAt period end2017-12-31$4.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-12-31$5.9mus-gaap:Liabilities
Shareholders' equityAt period end2017-12-31$721.2kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-18-001597. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.